Background: Using an emulsion-templated freeze-drying technique we have synthesised combination lopinavir/ritonavir (LPV/RTV) solid drug nanoparticles (SDNs) with 70% weight drug loading in the dry state and compared their antiretroviral activity and cellular accumulation in primary immune cells.
Methods: MT4 cells (NIBSC, UK) and primary immune cells (CD4+ T lymphocytes, CD56+ natural killer cells, CD14+ monocytes and monocyte-derived macrophages (MDM)) (Lonza, UK) from 4 donors, were incubated with either combination aqueous solutions or combination solid drug nanoparticle (SDN) suspensions at 10µM lopinavir (LPV; 0.1 µCi H3) and ritonavir (RTV) at 1:4, 1:8 or 1:40 ratio, for 60 minutes. Aliquots of media (extracellular) and lysed cells (intracellular) were sampled and a cellular accumulation ratio determined. Antiviral activity by combination SDNs and aqueous solutions were assessed against HIVIIIB infected MT4 cells at the same ratios. Data analysis was conducted using GraphPad Prism 3.0 and StatsDirect software.
Results: Cellular accumulation of LPV/RTV SDNs was higher than the equivalent aqueous solution in MT4 (1:4, 1.8-fold, p < 0.0001; 1:8, 1.7-fold, p < 0.0001 and 1:40; 2.0-fold p < 0.0001), CD4+ (1:4; 1.6-fold; p < 0.0001, 1:8; 1.7-fold p < 0.0001 and 1:40; 2.0-fold p < 0.0001), CD14+ (1:4; 1.1-fold; p = 0.03, 1:8; 1.2-fold p = 0.0002, 1:40; 1.5-fold; p = 0.0001), CD56+ (1:4; 1.4-fold; p < 0.0001, 1:8; 1.5-fold p < 0.0001, 1:40; 1.5-fold p < 0.0001) and MDM (1:4; 2.2-fold; p < 0.0001, 1:8; 2.3-fold p < 0.0001 and 1:40; 2.7-fold p < 0.0001). Activity against HIVIIIB in MT4 cells was higher for SDNs compared to aqueous solutions (1:4, IC50 = 10.1 ± 0.5nM versus 15.7 ± 0.3nM, p<0.0001; 1:8, IC50 = 14.9 ± 0.6 versus 24.1 ± 1.9nM, p<0.0001; 1:40, IC50 = 17.4 ± 0.7 versus 31.7 ± 1.2nM, p<0.0001, respectively) consistent with higher cellular accumulation.
Conclusions: Combination SDNs have increased cellular accumulation and enhanced antiviral activity in cell-based assays. Notably, equivalent protease inhibition in vitro with LPV doses requiring 10-fold less RTV was observed. Due to RTV intolerance and long-term toxicities associated with chronic exposure to RTV, strategies to reduce RTV dose are worthy of further investigation.